GSK's sales in China improving


GlaxoSmithKline's (GSK +1%) sales in China have been recovering since Q3, when revenue plummeted 61% following the emergence of accusations that the company bribed doctors.

"The trend is definitely looking a bit more positive," says CFO Simon Dingemans. "We can see the future opportunities to rebuild the business as and when we get to the other side of the (bribery) inquiry."

Meanwhile, a study from the Centers for Disease Control & Prevention has found that GSK's Rotarix vaccine for preventing severe diarrhea in infants could slightly increase the risk of bowel blockage. However, the problem isn't severe enough to warrant a change in recommendation for the vaccine's use.

An FDA report on Merck's (MRK -1%) RotaTeq has come to a similar conclusion.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs